Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $95
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $100 to $95.
Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $100 to $95.